Cargando…

Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lu, Wang, Xiaojuan, Wang, Rongrong, Hu, Yunzhen, Jiang, Saiping, Lu, Xiaoyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396737/ https://www.ncbi.nlm.nih.gov/pubmed/32801640 http://dx.doi.org/10.2147/DDDT.S259058

Ejemplares similares

Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats
por: HU, Yunzhen, et al.
Publicado: (2021)

On-ward participation of clinical pharmacists in a Chinese intensive care unit for patients with COVID-19: A retrospective, observational study
por: Wang, Rongrong, et al.
Publicado: (2021)

Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study
por: Jiang, Saiping, et al.
Publicado: (2020)

Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy
por: Li, Lu, et al.
Publicado: (2020)

TPGS-based and S-thanatin functionalized nanorods for overcoming drug resistance in Klebsiella pneumonia
por: Wang, Xiaojuan, et al.
Publicado: (2022)

Optimal control for COVID-19 pandemic with quarantine and antiviral therapy
por: Masud, Md. Abdullah Bin, et al.
Publicado: (2021)

Optimizing antiviral therapy for COVID-19 with learned pathogenic model
por: Dutta, Abhishek
Publicado: (2022)

Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
por: Shiraki, Kimiyasu, et al.
Publicado: (2022)

Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014
por: Yang, Ping, et al.
Publicado: (2018)

Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014
por: Yang, Ping, et al.
Publicado: (2020)

Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy
por: Ho, Ping, et al.
Publicado: (2021)

Special Issue “Efficacy and Safety of Antiviral Therapy”
por: Colpani, Agnese, et al.
Publicado: (2023)

Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
por: Mirtaleb, Mona Sadat, et al.
Publicado: (2021)

Antiviral agents for the treatment of COVID-19: Progress and challenges
por: Singh, Manmeet, et al.
Publicado: (2022)

Special Agents Can Promote Cooperation in the Population
por: Wang, Xin, et al.
Publicado: (2011)

Antiviral Therapy of COVID-19
por: Gudima, Georgii, et al.
Publicado: (2023)

Discovery of Flavone Derivatives Containing Carboxamide Fragments as Novel Antiviral Agents
por: Zhao, Bobo, et al.
Publicado: (2023)

Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19
por: Pindiprolu, Sai Kiran S.S., et al.
Publicado: (2020)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

COVID-19 in special populations
por: Yahav, Dafna
Publicado: (2022)

Antiviral Agents
por: Reines, Eric D., et al.
Publicado: (1988)

Antiviral Agents
por: Paintsil, E., et al.
Publicado: (2019)

Antiviral Agents
por: Paintsil, E., et al.
Publicado: (2009)

Antiviral therapy and immunotherapy of COVID-19
por: Crespillo, Clara, et al.
Publicado: (2021)

Elevation of Serum Cytokine Profiles and Liver Metabolomic Normalization in Early Convalescence of COVID-19 Patients
por: Lou, Yan, et al.
Publicado: (2021)

Discovery of Cysteine and Its Derivatives as Novel Antiviral and Antifungal Agents
por: Yang, Shan, et al.
Publicado: (2021)

Broad-spectrum antiviral agents
por: Zhu, Jun-Da, et al.
Publicado: (2015)

Trends and correlation of antibiotic susceptibility and antibiotic consumption at a large teaching hospital in China (2007–2016): a surveillance study
por: Wang, Rongrong, et al.
Publicado: (2019)

Bomidin: An Optimized Antimicrobial Peptide With Broad Antiviral Activity Against Enveloped Viruses
por: Liu, Rongrong, et al.
Publicado: (2022)

Special Issue “Advances in Antiviral Agents against SARS-CoV-2 and Its Variants”
por: Esposito, Francesca, et al.
Publicado: (2023)

COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine
por: Guan, Wenyi, et al.
Publicado: (2020)

Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19
por: Hu, Xi, et al.
Publicado: (2022)

Progresses in clinical studies on antiviral therapies for COVID‐19—Experience and lessons in design of clinical trials
por: Zhaori, Getu, et al.
Publicado: (2020)

Synthesis and Biological Activity of Novel Oxazinyl Flavonoids as Antiviral and Anti-Phytopathogenic Fungus Agents
por: Ma, Yucong, et al.
Publicado: (2022)

Interim Guidelines on Antiviral Therapy for COVID-19
por: Kim, Sun Bean, et al.
Publicado: (2020)

Early triple antiviral therapy for COVID-19
por: Lee, Nelson, et al.
Publicado: (2020)

Optimizing Spatial Allocation of COVID‐19 Vaccine by Agent‐Based Spatiotemporal Simulations
por: Zhou, Shuli, et al.
Publicado: (2021)

Pandemic COVID-19: Current status and challenges of antiviral therapies
por: Chan, Winglam, et al.
Publicado: (2020)

Curcumin as an Antiviral Agent
por: Jennings, Morgan R., et al.
Publicado: (2020)

Ribonucleases as antiviral agents
por: Ilinskaya, O. N., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_75b0g0n3heh9ter04oc9plnmu4